OctoPlus NV is a Netherlands-based drug delivery and drug development company. The Company’s activities include pharmaceutical development services, drug delivery technologies and product development. The products and drug delivery divisions focus on developing pharmaceutical products, including Locteron, for treating chronic hepatitis C viral infections; OP-145 CSOM; OP-286 CR; HBVOctoVAX, a vaccine against hepatitis B infections, and JEV-OctoVAX, a vaccine against Japanese encephalitis. The product development division specializes in providing services to life sciences companies in the field of drug formulation. On October 6, 2008 Octoplus sold the commercial rights of Locteron to Biotex Therapeutics Inc. As of December 31, 2008, OctoPlus NV had the following subsidiaries: OctoShare B.V., OctoPlus Development B.V., OctoPlus Technologies B.V., OctoPlus Sciences B.V., OctoPlus PolyActive Sciences B.V. (incorporated on September 9, 2008), Chienna B.V. and OctoPlus Inc. 
 
 

http://www.octoplus.nl/